By Jonathan Corum and Carl ZimmerUpdated June 4, 2021
https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 VariantList of authors.
Shabir A. Madhi, Ph.D.,
Vicky Baillie, Ph.D.,
Clare L. Cutland, Ph.D.,
Merryn Voysey, D.Phil.,
Anthonet L. Koen, M.B., B.Ch.,
Lee Fairlie, F.C.Paeds.,
Sherman D. Padayachee, M.B., Ch.B.,
Keertan Dheda, Ph.D.,
Shaun L. Barnabas, Ph.D.,
Qasim E. Bhorat, M.Sc.,
Carmen Briner, M.B., B.Ch.,
Gaurav Kwatra, Ph.D.,
et al.,
for the NGS-SA Group, and the Wits-VIDA COVID Group*
https://www.nejm.org/doi/full/10.1056/nejmoa2102214
Science Brief: Emerging SARS-CoV-2 Variants
Updated Jan. 28, 2021
Multiple SARS-CoV-2 variants are circulating globally. Several new variants emerged in the fall of 2020, most notably:
In the United Kingdom (UK), a new variant of SARS-CoV-2 (known as 20I/501Y.V1, VOC 202012/01, or B.1.1.7) emerged with a large number of mutations. This variant has since been detected in numerous countries around the world, including the United States (US). In January 2021, scientists from UK reported evidence[1] that suggests the B.1.1.7 variant may be associated with an increased risk of death compared with other variants. More studies are needed to confirm this finding. This variant was reported in the US at the end of December 2020.
In South Africa, another variant of SARS-CoV-2 (known as 20H/501Y.V2 or B.1.351) emerged independently of B.1.1.7. This variant shares some mutations with B.1.1.7. Cases attributed to this variant have been detected in multiple countries outside of South Africa. This variant was reported in the US at the end of January 2021.
In Brazil, a variant of SARS-CoV-2 (known as P.1) emerged that was first was identified in four travelers from Brazil, who were tested during routine screening at Haneda airport outside Tokyo, Japan. This variant has 17 unique mutations, including three in the receptor binding domain of the spike protein. This variant was detected in the US at the end of January 2021.
Scientists are working to learn more about these variants to better understand how easily they might be transmitted and the effectiveness of currently authorized vaccines against them. New information about the virologic, epidemiologic, and clinical characteristics of these variants is rapidly emerging.
CDC, in collaboration with other public health agencies, is monitoring the situation closely. CDC is working to detect and characterize emerging viral variants. Furthermore, CDC has staff available to provide technical support to investigate the epidemiologic and clinical characteristics of SARS-CoV-2 variant infections. CDC will communicate new information as it becomes available.
https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html
Above. Korn - Twisted Transistor
No comments:
Post a Comment